These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 34142388)

  • 1. Immunological mechanisms underlying progression of chronic wounds in recessive dystrophic epidermolysis bullosa.
    Huitema L; Phillips T; Alexeev V; Igoucheva O
    Exp Dermatol; 2021 Dec; 30(12):1724-1733. PubMed ID: 34142388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant recruitment of leukocytes defines poor wound healing in patients with recessive dystrophic epidermolysis bullosa.
    Phillips T; Huitema L; Cepeda R; Cobos DL; Perez RIM; Garza MS; Ringpfeil F; Dasgeb B; Uitto J; Salas-Alanis JC; Alexeev V; Igoucheva O
    J Dermatol Sci; 2020 Dec; 100(3):209-216. PubMed ID: 33143962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-145-5p regulates fibrotic features of recessive dystrophic epidermolysis bullosa skin fibroblasts.
    Condorelli AG; Logli E; Cianfarani F; Teson M; Diociaiuti A; El Hachem M; Zambruno G; Castiglia D; Odorisio T
    Br J Dermatol; 2019 Nov; 181(5):1017-1027. PubMed ID: 30816994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa.
    Venugopal SS; Yan W; Frew JW; Cohn HI; Rhodes LM; Tran K; Melbourne W; Nelson JA; Sturm M; Fogarty J; Marinkovich MP; Igawa S; Ishida-Yamamoto A; Murrell DF
    J Am Acad Dermatol; 2013 Dec; 69(6):898-908.e7. PubMed ID: 24075228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathomechanisms of Altered Wound Healing in Recessive Dystrophic Epidermolysis Bullosa.
    Cianfarani F; Zambruno G; Castiglia D; Odorisio T
    Am J Pathol; 2017 Jul; 187(7):1445-1453. PubMed ID: 28460207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptomic profiling of recessive dystrophic epidermolysis bullosa wounded skin highlights drug repurposing opportunities to improve wound healing.
    Onoufriadis A; Proudfoot LE; Ainali C; Torre D; Papanikolaou M; Rayinda T; Rashidghamat E; Danarti R; Mellerio JE; Ma'ayan A; McGrath JA
    Exp Dermatol; 2022 Mar; 31(3):420-426. PubMed ID: 34694680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance of chronicity signatures in fibroblasts isolated from recessive dystrophic epidermolysis bullosa chronic wound dressings under culture conditions.
    De Gregorio C; Catalán E; Garrido G; Morandé P; Bennett JC; Muñoz C; Cofré G; Huang YL; Cuadra B; Murgas P; Calvo M; Altermatt F; Yubero MJ; Palisson F; South AP; Ezquer M; Fuentes I
    Biol Res; 2023 May; 56(1):23. PubMed ID: 37161592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and molecular features in a cohort of Middle Eastern patients with epidermolysis bullosa.
    Bergson S; Daniely D; Bomze D; Mohamad J; Malovitski K; Meijers O; Briskin V; Bihari O; Malchin N; Israeli S; Mashiah J; Falik-Zaccai T; Avitan-Hersh E; Eskin-Schwartz M; Allon-Shalev S; Sarig O; Sprecher E; Samuelov L
    Pediatr Dermatol; 2023; 40(6):1021-1027. PubMed ID: 37827535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudosyndactyly - an inflammatory and fibrotic wound healing disorder in recessive dystrophic epidermolysis bullosa.
    Breitenbach J; Gruber C; Klausegger A; Trost A; Bogner B; Reitsamer H; Bauer JW
    J Dtsch Dermatol Ges; 2015 Dec; 13(12):1257-66. PubMed ID: 26612796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa.
    Tang JY; Marinkovich MP; Lucas E; Gorell E; Chiou A; Lu Y; Gillon J; Patel D; Rudin D
    Orphanet J Rare Dis; 2021 Apr; 16(1):175. PubMed ID: 33849616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell activation and bacterial infection in skin wounds of recessive dystrophic epidermolysis bullosa patients.
    Alexeev V; Huitema L; Phillips T; Cepeda R; de Los Cobos D; Perez RIM; Salas-Garza M; Fajardo-Ramirez OR; Ringpfeil F; Uitto J; Salas-Alanis JC; Igoucheva O
    Exp Dermatol; 2022 Sep; 31(9):1431-1442. PubMed ID: 35620886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey.
    Eng VA; Solis DC; Gorell ES; Choi S; Nazaroff J; Li S; de Souza MP; Murrell DF; Marinkovich MP; Tang JY
    J Am Acad Dermatol; 2021 Nov; 85(5):1161-1167. PubMed ID: 32199895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABCB5
    Dieter K; Niebergall-Roth E; Daniele C; Fluhr S; Frank NY; Ganss C; Kiritsi D; McGrath JA; Tolar J; Frank MH; Kluth MA
    Cytotherapy; 2023 Jul; 25(7):782-788. PubMed ID: 36868990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America.
    Feinstein JA; Jambal P; Peoples K; Lucky AW; Khuu P; Tang JY; Lara-Corrales I; Pope E; Wiss K; Hook KP; Levin LE; Morel KD; Paller AS; McCuaig CC; Powell J; Eichenfield LF; Price H; Levy ML; Schachner LA; Browning JC; Bayliss S; Jahnke M; Shwayder T; Glick SA; Bruckner AL
    JAMA Dermatol; 2019 Feb; 155(2):196-203. PubMed ID: 30586139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired Wound Healing, Fibrosis, and Cancer: The Paradigm of Recessive Dystrophic Epidermolysis Bullosa.
    Tartaglia G; Cao Q; Padron ZM; South AP
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa.
    Eichstadt S; Barriga M; Ponakala A; Teng C; Nguyen NT; Siprashvili Z; Nazaroff J; Gorell ES; Chiou AS; Taylor L; Khuu P; Keene DR; Rieger K; Khosla RK; Furukawa LK; Lorenz HP; Marinkovich MP; Tang JY
    JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31578311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa.
    Siprashvili Z; Nguyen NT; Gorell ES; Loutit K; Khuu P; Furukawa LK; Lorenz HP; Leung TH; Keene DR; Rieger KE; Khavari P; Lane AT; Tang JY; Marinkovich MP
    JAMA; 2016 Nov; 316(17):1808-1817. PubMed ID: 27802546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa.
    Cutlar L; Greiser U; Wang W
    Exp Dermatol; 2014 Jan; 23(1):1-6. PubMed ID: 24107073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basic fibroblast growth factor: a missing link between collagen VII, increased collagenase, and squamous cell carcinoma in recessive dystrophic epidermolysis bullosa.
    Arbiser JL; Fine JD; Murrell D; Paller A; Connors S; Keough K; Marsh E; Folkman J
    Mol Med; 1998 Mar; 4(3):191-5. PubMed ID: 9562977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ophthalmologic Approach in Epidermolysis Bullosa: A Cross-Sectional Study With Phenotype-Genotype Correlations.
    Mellado F; Fuentes I; Palisson F; I Vergara J; Kantor A
    Cornea; 2018 Apr; 37(4):442-447. PubMed ID: 29384803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.